Raphael Pharmaceutical Inc.

Healthcare US RAPH

0.23USD
-1.42(86.06%)

Last update at 2024-10-23T13:31:00Z

Day Range

0.230.23

LowHigh

52 Week Range

0.602.50

LowHigh

Fundamentals

Previous Close 1.65
Market Cap18.10M
Volume2915
P/E Ratio-
Dividend Yield-%
Revenue TTM0.00000M
Revenue Per Share TTM-
Gross Profit TTM 0.00000M
Diluted EPS TTM-0.17

Overview
Financials
Peer Comparison
Reports
Stock Research & News

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Type	yearly	yearly	yearly	yearly
Date	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Income before tax	-3.35800M	-1.62500M	-0.71800M	-
Minority interest	-	-	-	-
Net income	-3.35800M	-1.62500M	-0.71800M	-
Selling general administrative	2.14M	0.85M	0.24M	-
Selling and marketing expenses	-	-	-	-
Gross profit	-	-	-	-
Reconciled depreciation	-	-	-	-
Ebit	-3.31700M	-1.62900M	-0.70600M	-0.62200M
Ebitda	-3.31700M	-1.62900M	-0.70600M	-
Depreciation and amortization	-	-	-	-
Non operating income net other	-	-	-	-
Operating income	-3.31700M	-1.62900M	-0.70600M	-
Other operating expenses	-	-	-	-
Interest expense	-	-	-	-
Tax provision	-	-	-	-
Interest income	-	-	-	-
Net interest income	-0.04100M	0.00400M	-0.01200M	-
Extraordinary items	-	-	-	-
Non recurring	-	-	-	-
Other items	-	-	-	-
Income tax expense	-	-	-	-
Total revenue	0.00000M	0.00000M	0.00000M	-
Total operating expenses	3.32M	1.63M	0.71M	-
Cost of revenue	-	-	-	-
Total other income expense net	-	-	-	-
Discontinued operations	-	-	-	-
Net income from continuing ops	-3.35800M	-1.62500M	-0.71800M	-
Net income applicable to common shares	-3.35800M	-1.62500M	-0.71800M	-0.65000M
Preferred stock and other adjustments	-	-	-	-

Breakdown	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Type	yearly	yearly	yearly	yearly
Date	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Total assets	0.33M	0.42M	0.32M	-
Intangible assets	-	-	-	-
Earning assets	-	-	-	-
Other current assets	0.04M	-	-	-
Total liab	0.23M	0.29M	0.37M	-
Total stockholder equity	0.11M	0.13M	-0.04300M	-
Deferred long term liab	-	-	-	-
Other current liab	0.22M	-	-	-
Common stock	0.16M	0.13M	0.10M	-
Capital stock	0.16M	0.13M	0.10M	-
Retained earnings	-6.02500M	-2.66700M	-1.04300M	-0.32500M
Other liab	-	-	-	-
Good will	-	-	-	-
Other assets	-	-	-	-
Cash	0.29M	0.15M	0.10M	-
Cash and equivalents	-	-	-	-
Total current liabilities	0.23M	0.29M	0.37M	-
Current deferred revenue	-	-	-	-
Net debt	-	-	0.26M	-
Short term debt	-	-	-	-
Short long term debt	-	-	0.36M	-
Short long term debt total	-	-	-	-
Other stockholder equity	-	-	-	-
Property plant equipment	0.00200M	-	-	-
Total current assets	0.33M	0.42M	0.32M	0.21M
Long term investments	-	-	-	-
Net tangible assets	0.11M	0.13M	-0.04300M	0.21M
Short term investments	-	-	-	-
Net receivables	-	0.09M	0.03M	0.00200M
Long term debt	-	-	-	-
Inventory	-	-	-	-
Accounts payable	0.07M	0.11M	0.00000M	-
Total permanent equity	-	-	-	-
Noncontrolling interest in consolidated entity	-	-	-	-
Temporary equity redeemable noncontrolling interests	-	-	-	-
Accumulated other comprehensive income	-	-	-	-
Additional paid in capital	-	-	-	-
Common stock total equity	-	-	-	-
Preferred stock total equity	-	-	-	-
Retained earnings total equity	-	-	-	-
Treasury stock	-	-	-	-
Accumulated amortization	-	-	-	-
Non currrent assets other	-	-	-	-
Deferred long term asset charges	-	-	-	-
Non current assets total	0.00200M	0.00000M	0.00000M	-
Capital lease obligations	-	-	-	-
Long term debt total	-	-	-	-

Breakdown	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Type	yearly	yearly	yearly	yearly
Date	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Investments	-0.00200M	-	-	-
Change to liabilities	0.10M	0.23M	0.00000M	0.00000M
Total cashflows from investing activities	-0.00200M	-0.00200M	-0.00200M	-0.00200M
Net borrowings	-	0.17M	0.36M	0.36M
Total cash from financing activities	0.90M	1.48M	0.82M	1.07M
Change to operating activities	0.21M	-0.02800M	-0.06100M	-0.31600M
Net income	-3.35800M	-1.62500M	-0.71800M	-0.65000M
Change in cash	0.14M	0.06M	0.04M	0.10M
Begin period cash flow	0.15M	0.10M	0.05M	-
End period cash flow	0.29M	0.15M	0.10M	0.05M
Total cash from operating activities	-0.75900M	-1.41900M	-0.77900M	-0.96600M
Issuance of capital stock	0.90M	1.29M	0.47M	-
Depreciation	-	-	-	-
Other cashflows from investing activities	-	-	-	-
Dividends paid	-	-	-	-
Change to inventory	-	-	-	-
Change to account receivables	-	-	-	-
Sale purchase of stock	-	-	-	-
Other cashflows from financing activities	-	0.01M	0.01M	0.01M
Change to netincome	2.29M	2.29M	2.29M	2.29M
Capital expenditures	0.00200M	0.00200M	0.00200M	0.00200M
Change receivables	-	-	-	-
Cash flows other operating	-	-	-	-
Exchange rate changes	-	-	-	-
Cash and cash equivalents changes	-	-	-	-
Change in working capital	0.31M	0.21M	-0.06100M	-
Stock based compensation	2.29M	-	-	-
Other non cash items	-	-	-	-
Free cash flow	-0.76100M	-1.41900M	-0.77900M	-

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company	Change (USD)	Price (USD)	Trailing PE (x)	Forward PE (x)	Price Sales TTM (x)	Price to Book Value (x)	Enterprise Value to EBITDA (x)
RAPH Raphael Pharmaceutical Inc.	-1.42 86.06%	0.23	-	-	-	304.45	-7.0093
ZTS Zoetis Inc	-0.59 0.31%	188.92	40.18	30.96	10.67	17.60	11.27	26.18
MKKGY Merck KGaA ADR	-0.71 2.03%	34.20	21.25	14.93	3.10	2.14	3.60	12.98
MKGAF MERCK Kommanditgesellschaft auf Aktien	- -%	173.10	21.73	14.95	3.16	2.15	3.56	12.82
TAK Takeda Pharmaceutical Co Ltd ADR	-0.285 2.02%	13.85	32.67	11.53	0.01	0.87	0.02	0.07

Reports Covered

View All

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.